These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2306236)

  • 1. Regioselectivity and stereoselectivity in the metabolism of HMG-CoA reductase inhibitors.
    Vyas KP; Kari PH; Pitzenberger SM
    Biochem Biophys Res Commun; 1990 Feb; 166(3):1155-62. PubMed ID: 2306236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.
    Vickers S; Duncan CA; Vyas KP; Kari PH; Arison B; Prakash SR; Ramjit HG; Pitzenberger SM; Stokker G; Duggan DE
    Drug Metab Dispos; 1990; 18(4):476-83. PubMed ID: 1976071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
    Vyas KP; Kari PH; Pitzenberger SM; Halpin RA; Ramjit HG; Arison B; Murphy JS; Hoffman WF; Schwartz MS; Ulm EH
    Drug Metab Dispos; 1990; 18(2):203-11. PubMed ID: 1971574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Male-specific metabolism of simvastatin by rat liver microsomes.
    Uchiyama N; Kagami Y; Saitoh Y; Ohtawa M
    Chem Pharm Bull (Tokyo); 1991 Jan; 39(1):236-8. PubMed ID: 2049809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.
    Vyas KP; Kari PH; Prakash SR; Duggan DE
    Drug Metab Dispos; 1990; 18(2):218-22. PubMed ID: 1971576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-669,262, a potent HMG-CoA reductase inhibitor.
    Joshua H; Schwartz MS; Wilson KE
    J Antibiot (Tokyo); 1991 Mar; 44(3):366-70. PubMed ID: 2026562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation of lovastatin--III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes.
    Vyas KP; Kari PH; Wang RW; Lu AY
    Biochem Pharmacol; 1990 Jan; 39(1):67-73. PubMed ID: 2297361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 9. The synthesis and biological evaluation of novel simvastatin analogs.
    Hartman GD; Halczenko W; Duggan ME; Imagire JS; Smith RL; Pitzenberger SM; Fitzpatrick SL; Alberts AW; Bostedor R; Chao YS
    J Med Chem; 1992 Oct; 35(21):3813-21. PubMed ID: 1433193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat.
    Smith PF; Grossman SJ; Gerson RJ; Gordon LR; Deluca JG; Majka JA; Wang RW; Germershausen JI; MacDonald JS
    Toxicol Pathol; 1991; 19(3):197-205. PubMed ID: 1780636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex difference in metabolism of simvastatin by rat hepatic microsomes.
    Ohtawa M; Uchiyama N
    Eur J Drug Metab Pharmacokinet; 1992; 17(3):175-81. PubMed ID: 1490485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
    Vickers S; Duncan CA; Chen IW; Rosegay A; Duggan DE
    Drug Metab Dispos; 1990; 18(2):138-45. PubMed ID: 1971563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. 7. Modification of the hexahydronaphthalene moiety of simvastatin: 5-oxygenated and 5-oxa derivatives.
    Duggan ME; Alberts AW; Bostedor R; Chao YS; Germershausen JI; Gilfillan JL; Halczenko W; Hartman GD; Hunt V; Imagire JS
    J Med Chem; 1991 Aug; 34(8):2489-95. PubMed ID: 1875346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
    Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
    Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.
    Keller RK; Zhao Z; Chambers C; Ness GC
    Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of lovastatin by rat and human liver microsomes in vitro.
    Greenspan MD; Yudkovitz JB; Alberts AW; Argenbright LS; Arison BH; Smith JL
    Drug Metab Dispos; 1988; 16(5):678-82. PubMed ID: 2906589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regioselectivity and stereoselectivity in the metabolism of trans-1,2-dihydroxy-1,2-dihydrobenz[a]anthracene by rat liver microsomes.
    Vyas KP; van Bladeren PJ; Thakker DR; Yagi H; Sayer JM; Levin W; Jerina DM
    Mol Pharmacol; 1983 Jul; 24(1):115-23. PubMed ID: 6865920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
    Slater EE; MacDonald JS
    Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.